| Chronic Kidney Diseases

Nutropin AQ vs Renvela

Side-by-side clinical, coverage, and cost comparison for chronic kidney diseases.
Deep comparison between: Nutropin Aq Nuspin 10 vs Renvela with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.
Safety signalsRenvela has a higher rate of injection site reactions vs Nutropin Aq Nuspin 10 based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Renvela but not Nutropin Aq Nuspin 10, including UnitedHealthcare
Sign up to reveal the full AI analysis
Nutropin Aq Nuspin 10
Renvela
At A Glance
SC injection
Daily
Recombinant human growth hormone
Oral
Three times daily with meals
Phosphate binder
Indications
  • Somatotropin deficiency
  • Turner Syndrome
  • Chronic Kidney Diseases
  • Chronic Kidney Diseases
Dosing
Somatotropin deficiency (pediatric) Up to 0.3 mg/kg/week divided into daily SC injections; pubertal patients may use up to 0.7 mg/kg/week divided daily.
Somatotropin deficiency (adult) Weight-based: starting dose up to 0.006 mg/kg/day SC, max 0.025 mg/kg/day (age <=35 years) or 0.0125 mg/kg/day (age >35 years); or non-weight-based: starting dose approximately 0.2 mg/day SC with gradual titration every 1-2 months.
Chronic Kidney Diseases Up to 0.35 mg/kg/week divided into daily SC injections; therapy may continue until renal transplantation.
Turner Syndrome Up to 0.375 mg/kg/week divided into equal doses 3 to 7 times per week by SC injection.
Chronic Kidney Diseases (Adults) Starting dose 0.8-1.6 g orally three times daily with meals based on serum phosphorus level; titrate by 0.8 g per meal at two-week intervals to achieve target serum phosphorus.
Chronic Kidney Diseases (Pediatric, >=6 years) Starting dose 0.8-1.6 g three times daily with meals based on body surface area (BSA) category; titrate based on BSA category at two-week intervals for 6 weeks then every 4 weeks as needed.
Contraindications
  • Acute critical illness due to complications following open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure
  • Prader-Willi syndrome in children with severe obesity, history of upper airway obstruction or sleep apnea, or severe respiratory impairment
  • Active malignancy
  • Known hypersensitivity to somatropin or any excipient
  • Active proliferative or severe non-proliferative diabetic retinopathy
  • Closed epiphysis (for growth promotion in pediatric patients)
  • Bowel obstruction
  • Known hypersensitivity to sevelamer carbonate, sevelamer hydrochloride, or any excipient
Adverse Reactions
Most common Edema or peripheral edema (adults with GHD), arthralgias (adults with GHD), otitis media and ear disorders (Turner syndrome), injection site discomfort (pediatric GHD)
Serious Intracranial hypertension, glucose intolerance, slipped capital femoral epiphysis, scoliosis progression, leukemia, pancreatitis, severe hypersensitivity reactions, hypothyroidism, hypoadrenalism, lipoatrophy
Postmarketing Anaphylaxis, angioedema, leukemia, gynecomastia (children), pancreatitis, slipped capital femoral epiphysis, osteonecrosis
Most common (>5%) Vomiting, nausea, diarrhea, dyspepsia, abdominal pain, flatulence, constipation
Postmarketing Hypersensitivity, pruritus, rash, abdominal pain, bleeding gastrointestinal ulcers, colitis, ulceration, necrosis, fecal impaction, ileus, intestinal obstruction, intestinal perforation
Pharmacology
Somatropin is a recombinant human growth hormone that binds to dimeric GH receptors on target cell membranes, triggering intracellular signal transduction; pharmacodynamic effects include skeletal growth and protein synthesis mediated via IGF-1, as well as direct effects such as lipolysis.
Sevelamer carbonate is a non-absorbed phosphate-binding cross-linked polymer, free of metal and calcium, that binds phosphate in the gastrointestinal tract via ionic and hydrogen bonding, thereby decreasing phosphate absorption and lowering serum phosphorus concentrations.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Nutropin Aq Nuspin 10
  • Covered on 5 commercial plans
  • PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
View full coverage details ›
Renvela
  • Covered on 5 commercial plans
  • PA (1/12) · Step Therapy (4/12) · Qty limit (9/12)
View full coverage details ›
UnitedHealthcare
Nutropin Aq Nuspin 10
  • Covered on 4 commercial plans
  • PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
View full coverage details ›
Renvela
  • Covered on 4 commercial plans
  • PA (1/8) · Step Therapy (0/8) · Qty limit (0/8)
View full coverage details ›
Humana
Nutropin Aq Nuspin 10
  • Covered on 0 commercial plans
  • PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
View full coverage details ›
Renvela
  • Covered on 0 commercial plans
  • PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
View full coverage details ›
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Nutropin Aq Nuspin 10.
No savings programs available for Renvela.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
  • Verify eligibility with the payer.
  • Pull the right PA forms directly from the payer.
  • Submit, track & send live updates to your dashboard.
Utilize patient records to autofill forms with our AI in seconds.
Free to start · HIPAA compliant
Next Steps for Your Patient
Nutropin Aq Nuspin 10View full Nutropin Aq Nuspin 10 profile
RenvelaView full Renvela profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.